A PYMNTS Company

Bio-Rad, Qiagen Are In Talks Over $10B Merger

By  |  October 10, 2022

Bio-Rad Laboratories is talks to merge with Qiagen in a deal that may be valued at more than $10 billion, The Wall Street Journal reported on Monday, citing people familiar with the matter.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    While talks have been ongoing for some time, an agreement isn’t likely for a few weeks and the deal still may fall through, according to the report.

    Spokespersons at both companies weren’t immediately available to comment when contacted by MedTech Dive.

    Hercules, Calif.-based Bio-Rad makes various products for the life science research and clinical diagnostic markets. It has a market capitalization of just under $12 billion. Qiagen is a Germany-based diagnostics company, with a market capitalization of about $10 billion.

    Thermo Fisher attempted to buy Qiagen in 2020 in a deal that was initially valued at $11.5 billion. That transaction fell apart after failing to secure support from Qiagen’s shareholders. Thermo Fisher went on to acquire research contractor PPD last year for $17.4 billion.

    The report of a Bio-Rad tie up with Qiagen comes amid a lull of medtech mergers and acquisitions following a spending spree last year. Notable acquisitions this year include Stryker’s $3 billion purchase of Vocera Communications, ResMed’s approximately $1 billion pickup of MediFox Dan and Becton Dickinson’s $1.53 billion purchase of Parata Systems.

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.